Projects per year
Personal profile
Biography
Associate Professor Miles Sparrow is a gastroenterologist specialising in inflammatory bowel disease (IBD) who is the Director of the IBD Unit at The Alfred Hospital, Melbourne and Adjunct Clinical Associate Professor at Monash University.
His research interests include use and optimisation of immunomodulators, therapeutic drug monitoring, novel E-Health models of care in IBD and clinical trials of novel experimental agents in IBD. He is a member of the Australian-IBD Association, IBD-Melbourne and BRIDGe IBD special interest groups, and is a faculty member of the Cornerstones IBD medical education program.
Research interests
Inflammatory bowel disease clinical trials of experimental new agents
Therapeutic drug monitoring in inflammatory bowel disease of thiopurine immunomodulators and biologic agents
Novel models of care including E-Health in inflammatory bowel disease
Supervision interests
Inflamatory bowel disease clinical research.
Currently qualified to supervise BMedSci medical students and to co-supervise graduate research students. Currently applying for AQF Level 10 qualification to enable primary supervision of gradulat research students.
Clinical activities
Director, Alfred Hospital Inflammatory Bowel Disease Unit and Inflammatory Bowel Disease Clinical Trials program.
Works in private practice at Brighton Gastroenterology Associates.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, MBBS, University of Melbourne
… → 1995
Research area keywords
- inflammatory bowel disease
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Ulcerative Colitis
Sparrow, M. (Primary Chief Investigator (PCI))
24/10/25 → 24/10/27
Project: Research
-
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis
Sparrow, M. (Primary Chief Investigator (PCI))
21/05/25 → 20/05/27
Project: Research
-
A placebo-controlled Phase IIa study to evaluate the efficacy and safety of AZD7798 in patients with moderate to severe Crohn’s disease
Sparrow, M. (Primary Chief Investigator (PCI))
23/04/25 → 22/04/27
Project: Research
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
Sparrow, M. (Primary Chief Investigator (PCI)), Croft, A. (Partner Investigator (PI)), Leong, R. W. L. (Partner Investigator (PI)), Sandhu, M. (Partner Investigator (PI)), Begun, J. (Chief Investigator (CI)) & Shaikh, A. (Partner Investigator (PI))
22/10/24 → 12/09/28
Project: Research
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis
Sparrow, M. (Primary Chief Investigator (PCI))
11/09/24 → 11/09/27
Project: Research
-
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Leong, R., Sakiris, A., Arzivian, A., Chetwood, J., Chaemsupaphan, T., Sparrow, M., Kamm, M., Kariayawasam, V. & for the Australian IBD Consensus Working Group, Jan 2025, In: Alimentary Pharmacology & Therapeutics. 61, 1, p. 132-144 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes—Authors' Reply
Swaminathan, A., Sparrow, M. P. & Gearry, R. B., Jan 2025, In: Alimentary Pharmacology & Therapeutics. 61, 2, p. 408-409 2 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero
Prentice, R., Flanagan, E., Wright, E. K., Gibson, P. R., Rosella, S., Rosella, O., Begun, J., An, Y. K., Lawrance, I. C., Kamm, M. A., Sparrow, M., Goldberg, R., Prideaux, L., Vogrin, S., Kiburg, K. V., Ross, A. L., Burns, M. & Bell, S. J., Jan 2025, In: Clinical Gastroenterology and Hepatology. 23, 1, p. 124-133.e7 17 p.Research output: Contribution to journal › Article › Research › peer-review
15 Citations (Scopus) -
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease
Systrom, H. K., Rai, V., Singh, S., Baidoo, L., Cheifetz, A. S., Devlin, S. M., Gecse, K. B., Irving, P. M., Kaplan, G. G., Kozuch, P. L., Ullman, T., Sparrow, M. P., Melmed, G. Y. & Siegel, C. A., Feb 2025, In: American Journal of Gastroenterology. 120, 2, p. 420-430 11 p.Research output: Contribution to journal › Article › Research › peer-review
5 Citations (Scopus) -
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study
Little, R. D., Swaine, A., Reynolds, R., Gibson, D. J., Barrau, M., D'Errico, F., Hampal, R., Sparrow, M. P., Roblin, X., Irving, P. M. & Ward, M. G., 3 Oct 2024, In: Inflammatory Bowel Diseases. 30, 10, p. 1714-1723 10 p.Research output: Contribution to journal › Article › Research › peer-review
1 Citation (Scopus)